| Literature DB >> 25990945 |
Oliver Bischof1,2, Ricardo Iván Martínez-Zamudio1,2.
Abstract
Cellular senescence is a stress response to a variety of extrinsic and intrinsic insults that cause genomic or epigenomic perturbations. It is now widely recognized as a potent tumor suppressor mechanism as well as a biological process impacting aging and organismal development. Like other cell fate decisions, senescence is executed and maintained by an intricate network of transcription factors (TFs), chromatin modifiers, and noncoding RNAs (ncRNAs). Altogether, these factors cooperate to implement the gene expression program that initiates and sustains the senescent phenotype. In the context of senescence, microRNAs (miRs) and long ncRNAs have been found to play regulatory roles at both the transcriptional and post-transcriptional levels. In this review, we discuss recent developments in the field and point toward future research directions to gain a better understanding of ncRNAs in senescence.Entities:
Keywords: RNA interference; aging; chromatin; noncoding RNA; senescence; transcription factors; transcriptional regulation
Mesh:
Substances:
Year: 2015 PMID: 25990945 PMCID: PMC5008183 DOI: 10.1002/iub.1373
Source DB: PubMed Journal: IUBMB Life ISSN: 1521-6543 Impact factor: 3.885
Figure 1Biomarkers of senescence. (a) Senescence is a stable growth arrest that is orchestrated by the p53/p21 and/or RB/p16 tumor suppressor pathways. Biomarkers of the senescence phenotype may include: 1) increased senescence‐associated β‐galactosidase activity (SA‐βGal); 2) reorganization of chromatin architecture as exemplified by senescence‐associated heterochromatic foci (SAHF) and reflected by a dramatic change in gene expression profile; 3) acquisition of a senescence‐associated secretory phenotype (SASP) that can enforce senescence in autocrine/juxtacrine and paracrine fashion (arrows); 4) constitutive senescence‐associated DNA damage foci (SDF); and 5) extensive cytoskeletal rearrangements characterized by a flat cell morphology. (b) Schematic representation of the two major senescence‐effector pathways (i.e., p53/p21 and RB/p16). Several senescence‐inducing stimuli such as hyperactivated oncogenes, DNA damage, cytokines, and therapeutic agents can activate these pathways to induce senescence.
Figure 2Functions of miRs in senescence. In the cytoplasm (top half of figure), canonical post‐transcriptional gene silencing (PTGS), involving translational suppression and transcript degradation, modulates senescence. Senescence bypass is often observed when miRs affect mRNAs coding for prosenescence factors like p21, p16, p53, or RB, whereas senescence induction may be achieved by targeting mRNAs coding for pro‐proliferative, DNA repair, and transcription factor (TF) genes. A miR/AGO2 containing corepressor complex facilitates the onset of senescence via a noncanonical nuclear function by recruiting RB and chromatin‐modifying complexes to pro‐proliferation E2F target genes (bottom half of figure). This process installs a repressive chromatin environment (i.e., H3K9me3 and H3K27me3) and engages transcriptional gene silencing (TGS). The presence of histone‐modifying enzymes SUV39H, PRC1, and PRC2 at these promoters is assumed and needs to be experimentally established. Wavy blue lines indicate hybridization between a miR and a putative target promoter RNA and/or target promoter DNA.
miRs and lncRNAs in cellular senescence
| MiRs/lncRNA | Cell type/tissue | Animal model | Species | Effect on senescence | Possible target/mechanism | Reference |
|---|---|---|---|---|---|---|
| MiR‐16 | Mammary/lung epithelial cells | N/A | Hs | – | N/A |
|
| MiR‐21 | Mammary/lung epithelial cells | N/A | Hs | – | N/A |
|
| MiR‐382 | Mammary/lung epithelial cells | N/A | Hs | – | N/A |
|
| MiR‐106b | Mammary epithelial cells | N/A | Hs | – | p21 3′UTR |
|
| MiR‐378a‐5p | Fibroblasts | N/A | Hs | – | Interference with activation of the p16 pathway |
|
| MiR‐146a/b | HUVECs, fibroblasts | N/A | Hs | – | NOX4a 3′UTR, reduced IRAK expression |
|
| MiR‐449a | Fibroblasts | ERCC1−/− | Mm | – | N/A |
|
| MiR‐445 | Fibroblasts | ERCC1−/− | Mm | – | N/A |
|
| MiR‐128 | Fibroblasts | ERCC1−/− | Mm | – | N/A |
|
| MiR‐19b | HeLa, MCF7, and HuH | N/A | Hs | – | Interference with activation of the p53 pathway |
|
| Dicer | Skin | Dicer conditional; Dicer−/− | Mm | – | N/A |
|
| DGCR8 | Fibroblasts | N/A | Hs; Mm | – | Interference with activation of the p53 pathway |
|
| MiR‐519 | Fibroblasts | N/A | Hs | + | HuH 3′UTR, p53/p21 and Rb/p16 pathway activation, increased SASP |
|
| MiR‐26b | Mammary epithelial cells | N/A | Hs | + | PRC2 members 3′UTR |
|
| MiR‐181a | Mammary epithelial cells | N/A | Hs | + | PRC2 members 3′UTR |
|
| MiR‐210 | Mammary epithelial cells | N/A | Hs | + | PRC2 members 3′UTR |
|
| MiR‐424 | Mammary epithelial cells | N/A | Hs | + | PRC2 transcriptional repression |
|
| MiR‐22 | Cardiac fibroblast | N/A | Mm | + | N/A |
|
| MiR‐24 | Cardiac fibroblast | N/A | Mm | + | N/A |
|
| MiR‐29a/b | Kidney, lung, heart, and liver; skeletal muscle | Kl−/−; N/A | Mm; Rn | + | Type IV collagens 3′UTR; IGF1, p85α, and MYBL2 3′UTRs |
|
| MiR‐494 | Fibroblasts | N/A | Hs | + | HnRNPA3, RAD32B, and SYNCRIP 3′UTRs |
|
| MiR‐34 | RCC; CLL | N/A | Hs | + | NOTCH1, E2F1, CDK6, and SIRT1 3′UTRs; p53 pathway activation |
|
| MiR‐449 | HCC; PCC; LCC | Gastrin−/−, | Hs; Mm | + | MYC, CDK6, and CCNE2 3′UTRs; CCND1 3′UTR, Rb pathway activation; E2F3 3′UTR |
|
| MiR‐335 | hMSCs | N/A | Hs | + | Activation of p16 pathway |
|
| MiR‐212 | HepG‐2 | N/A | Hs | + | Activation of p16 pathway |
|
| H19/miR‐675 | Prostate | Pten prostate conditional deletion | Mm | – | RB 3′UTR |
|
| let7 | Fibroblasts | N/A | Hs | + | Recruitment of AGO2/HDAC complex to E2F target gene promoters |
|
| ANRIL | Fibroblasts and PCC | N/A | Hs | – | Recruitment of PRC1 to the INK4 locus |
|
| PANDA | Fibroblasts | N/A | Hs | +/− | Recruitment of SAFA/BMI1 to target promoters/sequestration of NF‐YA |
|
| HOTAIR | HeLa | N/A | Hs | + | Facilitates ubiquitination of ATXN1 and Snurportin |
|
| TERRA | HeLa; fibroblasts | N/A | Hs | +/− | Recruitment of shelterin proteins/recruitment of LSD1/MRE11 complex |
|
Abbreviations: N/A, not available; Hs, Homo sapiens; Mm, Mus musculus; HUVECs, human umbilical vein endothelial cells; CLL, chronic lymphocytic leukemia; RCC, renal cell carcinoma; LCC, lung cell carcinoma; PCC, prostate cancer cell.
Figure 3Senescence regulation by lncRNAs. (a) LncRNAs recruit PRC1 and PRC2 complexes to target promoters to modulate senescence via gene silencing. Recruitment may be direct operating in cis (i.e., CBX7 directly binds nascent ANRIL at the INK4 locus) or indirect operating in trans via an adaptor molecule (i.e., PANDA‐mediated bridging between SAFA and BMI1 at target genes). (b) Noncoding transcription of TERRA at telomeres maintains telomere homeostasis by recruiting shelterin proteins (e.g., TRF2). In the absence of TRF2 (which occurs in replicative senescence due to telomere attrition), TERRA facilitates a DNA damage response (DDR) by recruiting an LSD1/MRE11 complex thus promoting senescence. Wavy blue lines indicate putative hybridization between lncRNA and a target promoter or other gene‐regulatory region.